[ad_1]
Ambrosia – the start-up that injects the plasma of young people in their 35s and over – is looking to settle in New York.
Chief Operating Officer David Cavalier told Gizmodo in an email that the company was considering "several possible locations in Manhattan" and hopes to open the clinic by the end of the year. Ambrosia also plans to open clinics "on other major markets in the Northeast and the rest of the United States," said Cavalier, adding that "the opening of the New York City Clinic City will not happen before the first quarter. 2019.
Ambrosia shares its name with the mythical food associated with immortality. To date, the company has conducted clinical trials that involved injecting the blood of young individuals into older adults to combat the "symptoms" of aging, according to CNBC. Ambrosia's treatments cost $ 8,000 for two liters of blood, but Cavalier said the company did not have a fixed price for his New York clinic yet.
According to Business Insider, Ambrosia has received about a hundred treatment inquiries in the past week since its website update. Nearly 150 patients aged 35 to 92 years would have been treated with Ambrosia and about half of them had participated in the company's clinical trial.
In June of last year, Ambrosia founder Jesse Karmazin told Mic that the company buys blood from blood samples and is confident about the outcome of the treatments. "I want to be clear at this point, it works," Karmazin said last year. "It reverses aging. We are quite clear at this point. This is conclusive. We have probably completed the clinical trial. It worked so well that we will start treating people. We are quite surprised by this. Yeah, no, it works, there really is no doubt that it works or not.
The experts cast doubt on the treatment of Ambrosia, citing lawsuits too small and simple to make decisive statements. "This is an unproven cure," said Dr. Phuoc V. Le, an assistant professor at the School of Public Health at the University of California at Berkeley and Associate Professor of Internal Medicine at the University of California. the School of Medicine at the University of San Francisco.
However, Cavalier's statement to Gizmodo contrasts Karmazin's earlier comments. "Ambrosia's message is that the young plasma [has] the possibility of fighting against aging and related syndromes, "said Cavalier. "What we have seen in the clinical trial and in clinical experience with patients is promising."
A lot of money has been channeled to science, like Ambrosia, with investors and technology elites involved in fraud. Among Silicon Valley's prominent figures who have explored this area are Peter Thiel, who may or may not have had a direct interest in Ambrosia, but described the concept of a "very interesting" youth blood injection in an interview. with Inc., a billionaire co-founder of PayPal, secretly funded a lawsuit that led to the bankruptcy of Gizmodo's former owner, Gawker Media.
Ambrosia plans to release data from its first clinical trial, which Karmazin describes as "very positive". But as long as these results will not be made public, you will simply have to take the word from the company that the patients are getting positive results. In a few months, people may have the opportunity to discover themselves, since they are a certain age with thousands of dollars to spend.
[Business Insider]Source link
